Celldex Therapeutics to Present at the Wedbush PacGrow 2012 Life Sciences: Management Access Conference

Celldex Therapeutics to Present at the Wedbush PacGrow 2012 Life Sciences: Management Access Conference

<0> Celldex Therapeutics, Inc.Anthony S. Marucci, 781-433-0771President and CEOorAvery W. Catlin, 781-433-0771Chief Financial OfficerorBMC CommunicationsBrad Miles, 646-513-3125 </0>

(Nasdaq: CLDX) today announced that Anthony S. Marucci, President and Chief Executive Officer of Celldex Therapeutics, Inc., will present at the Wedbush PacGrow 2012 Life Sciences: Management Access Conference in New York City on Wednesday, August 15, 2012 at 9:45 a.m. ET. A live webcast of the Company’s presentation will be available online on the “Presentations” page of the “Investors” section of the Celldex website at and will be archived for 30 days following the event.

Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. For more information, please visit .

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.